Last reviewed · How we verify
Nab-paclitaxel Combined With Bevacizumab
Nab-paclitaxel Combined With Bevacizumab is a Small molecule drug developed by Peking University. It is currently in Phase 2 development.
At a glance
| Generic name | Nab-paclitaxel Combined With Bevacizumab |
|---|---|
| Sponsor | Peking University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Nausea
- Neutropenia
- Alopecia
- Diarrhoea
- Constipation
- Anaemia
- Dyspnoea
- Cough
- Vomiting
- Epistaxis
- Rash
Key clinical trials
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer (PHASE1, PHASE2)
- Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) (PHASE2)
- Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma (PHASE2)
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nab-paclitaxel Combined With Bevacizumab CI brief — competitive landscape report
- Nab-paclitaxel Combined With Bevacizumab updates RSS · CI watch RSS
- Peking University portfolio CI
Frequently asked questions about Nab-paclitaxel Combined With Bevacizumab
What is Nab-paclitaxel Combined With Bevacizumab?
Nab-paclitaxel Combined With Bevacizumab is a Small molecule drug developed by Peking University.
Who makes Nab-paclitaxel Combined With Bevacizumab?
Nab-paclitaxel Combined With Bevacizumab is developed by Peking University (see full Peking University pipeline at /company/peking-university).
What development phase is Nab-paclitaxel Combined With Bevacizumab in?
Nab-paclitaxel Combined With Bevacizumab is in Phase 2.
What are the side effects of Nab-paclitaxel Combined With Bevacizumab?
Common side effects of Nab-paclitaxel Combined With Bevacizumab include Fatigue, Nausea, Neutropenia, Alopecia, Diarrhoea, Constipation.